BFM
CORT icon

Boothbay Fund Management’s Corcept Therapeutics CORT Stock Holding History

Boothbay Fund Management’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-54,448
Closed -$1.89M – 2128
2025
Q4 		$1.89M Buy
+54,448
New +$4.28M 0.03% 582
2024
Q4 		– Sell
-8,271
Closed -$383K – 1554
2024
Q3 		$383K Buy
+8,271
New +$294K 0.01% 1106
2019
Q1 		– Sell
-34,452
Closed -$460K – 770
2018
Q4 		$460K Buy
+34,452
New +$455K 0.07% 281
2016
Q2 		– Sell
-10,450
Closed -$49K – 547
2016
Q1 		$49K Buy
10,450
+257
+3% +$1K 0.01% 560
2015
Q4 		$51K Buy
+10,193
New +$46K 0.02% 530

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

Boothbay Fund Management's CORT Position: Q1 2026 in Review

Boothbay Fund Management sold out of Corcept Therapeutics (CORT) in Q1 2026, closing a stake of 54,448 shares — an estimated $1.89M sold.

Boothbay Fund Management first reported a position in CORT in Q4 2015 and held it in 5 quarters. The position peaked at $1.89M in Q4 2025. 352 funds tracked by Wall St. Rank hold CORT as of Q1 2026.

  • Boothbay Fund Management reported no remaining Corcept Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Boothbay Fund Management sold 54,448 Corcept Therapeutics shares in Q1 2026, an estimated $1.89M.
  • Boothbay Fund Management first reported a position in Corcept Therapeutics in Q4 2015 and held it in 5 quarters.
  • Boothbay Fund Management's Corcept Therapeutics position peaked at $1.89M in Q4 2025.
  • 352 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q1 2026.

Based on Boothbay Fund Management's 13F filing for Q1 2026, filed 15 May 2026.